All Search Results
-
POWER
Establishment of the Pediatric Obesity Weight Evaluation Registry (POWER): A prospective pilot project of children and adolescents presenting for weight management.
-
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
A Phase 1/2, Open-Label, Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity Study of Repotrectinib in Pediatric and Young Adult Subjects With Advanced or Metastatic Malignancies Harboring ALK, ROS1, NTRK1-3 Alterations
-
Unbalanced Atrioventricular Septal Defect Study
Unbalanced Atrioventricular Septal Defect: A Congenital Heart Surgeons' Society Inception Cohort Study
-
Children’s Brain Tumor Network (CBTN) Collection Protocol
Children’s Brain Tumor Network (CBTN) Collection Protocol
-
Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma
Phase II Trial of Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma
-
The Association of Kawasaki Disease and COVID-19 with Cardiac Complications:
The Association of Kawasaki Disease and COVID-19 with Cardiac Complications: A Focused Sub-study of the International Kawasaki Disease Registry (IKDR)
-
DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma
Phase II Trial of Eflornithine/DFMO as Maintenance Therapy for Molecular High Risk/Very High Risk and Relapsed/Refractory Medulloblastoma
-
A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis
An Open-Label, Single-Arm Study to Evaluate the Efficacy, Pharmacokinetics, and Safety of Etrasimod in Adolescent Subjects with Moderately to Severely Active Ulcerative Colitis
-
A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease (HIBISCUS)
4202-HEM-301: An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral Etavopivat, a Pyruvate Kinase Activator in Patients With Sickle Cell Disease (HIBISCUS)
-
Research Study on How Well Concizumab Works for You if You Have Haemophilia A or B With or Without Inhibitors (Explorer10)
Open-label Study Investigating Efficacy, Safety and Pharmacokinetics of Concizumab Prophylaxis in Children Below 12 Years With Haemophilia A or B With or Without Inhibitors
